{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:30Z","timestamp":1783977210624,"version":"3.55.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Marginal zone lymphomas (MZL) are indolent lymphomas that may undergo transformation into aggressive lymphomas, most frequently diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (LONCA) is an antibody\u2013drug conjugate used in the treatment of relapsed\/refractory large B-cell lymphomas. Here we present the clinical case of a patient with nodal transformed DLBCL and concomitant bone marrow involvement by indolent lymphoma successfully treated with LONCA. However the therapy was discontinued after six cycles as the patient developed treatment-related bone marrow aplasia. This case raises concerns about prolonged hematologic toxicity of LONCA, particularly in patients with pre-existing marrow involvement while highlights the potential of this drug to induce deep and durable response, even after limited exposure.<\/jats:p>","DOI":"10.1007\/s00277-026-07050-9","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:23:22Z","timestamp":1778477002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report"],"prefix":"10.1007","volume":"105","author":[{"given":"Lorenzo","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cappuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"7050_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, The World Health Organization Classification of Haematolymphoid Tumours (2022) Correction: The 5th edition of: Lymphoid Neoplasms Leukemia. 36(7):1720\u20131748. Leukemia. 2023;37(9):1944\u20131951. https:\/\/doi.org\/10.1038\/s41375-023-01962-5","DOI":"10.1038\/s41375-023-01962-5"},{"issue":"23","key":"7050_CR2","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1182\/bloodadvances.2024013188","volume":"8","author":"C Bommier","year":"2024","unstructured":"Bommier C, Link BK, Gysbers BJ et al (2024) Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv 8(23):5939\u20135948. https:\/\/doi.org\/10.1182\/bloodadvances.2024013188","journal-title":"Blood Adv"},{"issue":"11","key":"7050_CR3","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, von Aprile K et al (2015) Histologic transformation in marginal zone lymphomas\u2020. Ann Oncol 26(11):2329\u20132335. https:\/\/doi.org\/10.1093\/annonc\/mdv368","journal-title":"Ann Oncol"},{"issue":"6","key":"7050_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(21)00139-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"7050_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol 204(3):784\u2013804. https:\/\/doi.org\/10.1111\/bjh.19236","journal-title":"Br J Haematol"},{"key":"7050_CR6","doi-asserted-by":"publisher","first-page":"118114","DOI":"10.1016\/j.ejmech.2025.118114","volume":"300","author":"X Zheng","year":"2025","unstructured":"Zheng X, Zhao Y, Miao Y, Zheng C (2025) Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications. Eur J Med Chem 300:118114. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118114","journal-title":"Eur J Med Chem"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07050-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:02:16Z","timestamp":1783976536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":6,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7050"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07050-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8795918\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the individual for the publication of any potentially identifiable data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"313"}}